MedTrace Logo

Implementing & Testing Assessment and Referral Technologies in Juvenile Justice

NCT01372046 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2011-06-13

No results posted yet for this study

Summary

1. Assess the impacts of implementing a juvenile assessment, referral, placement, and treatment planning (J-ARPP) protocol, and of different strategies for transferring J-ARPP technology, on service utilization of youth entering the juvenile justice system.
2. Assess the impacts of implementing J-ARPP, and of different strategies for transferring J-ARPP technology, on measures of organizational readiness and motivation, and staff attitudes about assessment and service.
3. Assess the impacts of implementing J-ARPP, and of different strategies for transferring J-ARPP technology, on measures of systems integration.
4. Assess fidelity to the J-ARPP protocol and the relationship between fidelity to the J-ARPP protocol and service utilization of youth entering the juvenile justice system.

Conditions

  • Skill Development of Staff
  • Use of Standardized Assessment Tools

Interventions

BEHAVIORAL

Booster Sessions

Provides onsite booster sessions for one year to the group after participating in standard care

BEHAVIORAL

Training

memorandums, staff meetings

Sponsors & Collaborators

  • University of Maryland

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • George Mason University

    lead OTHER

Principal Investigators

  • Faye Taxman, Ph.D. · George Mason University

  • Doug Young, MA · University of Maryland

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-12-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01372046 on ClinicalTrials.gov